How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Document

    Has all of the relevant evidence been taken into account?

  • Question on Document

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Document

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Document

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?
The content on this page is not current guidance and is only for the purposes of the consultation process.

1 Recommendations

Closed for comments This consultation ended on at   Request commenting lead permission

Conclusion

Recommendations

3.17

The committee took into account its preferred assumptions, and the key uncertainties in overall survival modelling and QALY shortfall calculations informing the severity modifier. It concluded that trifluridine–tipiracil plus bevacizumab is unlikely to represent a cost-effective use of NHS resources, and that further analyses were needed to inform decision making. So, it could not recommend trifluridine–tipiracil plus bevacizumab for treating mCRC after 2 systemic treatments.